Merck KGaA/€MRK

07:00
09:10
11:15
13:25
15:30
1D1W1MYTD1Y5YMAX

About Merck KGaA

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.

Ticker

€MRK

Primary listing

XETRA

Industry

Pharmaceuticals
Headquarters

Employees

62,604

ISIN

DE0006599905

Merck KGaA Metrics

BasicAdvanced
€48B
17.03
€6.48
0.64
€2.20
1.99%

What the Analysts think about Merck KGaA

Analyst ratings (Buy, Hold, Sell) for Merck KGaA stock.

Bulls say / Bears say

Merck KGaA's acquisition of SpringWorks Therapeutics for $3.9 billion enhances its rare cancer treatment portfolio, potentially driving future revenue growth. (reuters.com)
The company anticipates currency-adjusted operating earnings growth of up to 8% in 2025, supported by strong demand for semiconductor chemicals and laboratory equipment used in biotech drug production. (reuters.com)
Goldman Sachs initiated coverage on Merck KGaA with a 'Buy' rating and a price target of EUR205.00, citing a positive outlook for the company's Life Science sector recovery extending into 2025 and 2026. (investing.com)
Merck KGaA issued a more cautious earnings outlook for 2025 due to macroeconomic and geopolitical uncertainties, as well as foreign-exchange headwinds, adjusting its adjusted EBITDA forecast to €5.8 billion to €6.4 billion from the previous €6.1 billion to €6.6 billion. (reuters.com)
The company faces challenges from expiring drug patents, prompting the acquisition of SpringWorks Therapeutics to bolster its pipeline, indicating potential revenue declines from existing products. (reuters.com)
Merck KGaA's Life Science division, its largest business segment, is affected by ongoing concerns over tariffs, leading to a slight adjustment in guidance for this sector. (reuters.com)
Data summarised monthly by Lightyear AI. Last updated on 30 Jun 2025.

Merck KGaA Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Merck KGaA Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy €MRK

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs